natgillin/translations-raw huggingface dataset:
There is no evidence that other drugs that reduce stomach acid such as H2 blockers or antacids interfere with antiplatelet activity of clopidogrel.
Ni dokazov, da druga zdravila za zmanjševanje želodčne kisline, npr. antagonisti histaminskih receptorjev H2 ali antacidi, ovirajo antitrombocitno delovanje klopidogrela.
There is no evidence that PritorPlus would reduce or prevent diuretic-induced hyponatraemia.
Ni podatkov, ki bi kazali, da zdravilo PritorPlus zmanjša ali prepreči hiponatriemijo, ki jo povzročajo diuretiki.
There is no evidence that Tolucombi would reduce or prevent diuretic-induced hyponatraemia.
Ni podatkov, ki bi kazali, da zdravilo Tolucombi zmanjša ali prepreči hiponatriemijo, ki jo povzročajo diuretiki.
There is no evidence to indicate that Simulect has an effect on your ability to drive a car or use machines.
Ni znakov, ki bi kazali, da bi Simulect vplival na vašo sposobnost upravljanja vozil in strojev.
There is no evidence to indicate that Zenapax has an effect on your ability to drive a car or operate machinery.
Ni znano, da bi Zenapax vplival na sposobnost za vožnjo z avtom ali upravljanje s stroji.
There is no evidence to suggest that any special precautions are needed when older people are treated – although experience with Soliris in this patient population is still limited.
Ni dokazov, da bi bili pri zdravljenju starejših ljudi potrebni posebni previdnostni ukrepi – čeprav so izkušnje z zdravilom Soliris pri tej populaciji bolnikov še vedno omejene.
There is no evidence to suggest that eptotermin alfa alters fertility.
Ni dokazov, da bi eptotermin alfa vplival na plodnost.
There is no evidence to suggest that there is an interaction between Ketoconazole HRA and other steroidogenesis inhibitors (ie metyrapone).
Ni dokazov o medsebojnem delovanju zdravila Ketokonazol HRA in drugih zaviralcev steroidogeneze (tj. metirapona).
There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients not already undergoing haemodialysis.
Ni znakov, ki bi podprli uvedbo hemodialize za preprečevanje ali zdravljenje NSF pri bolnikih, ki še niso na hemodializi.
There is no evidencefor immunotoxic, dermal irritation, or phototoxic potential.
Ni znakov možne imunotoksičnosti, kožnega draženja ali fototoksičnosti.
There is no excretion, as conestat alfa is cleared from the circulation via receptor-mediated endocytosis followed by complete hydrolysis/degradation in the liver.
Izločanja v obliki nespremenjenega konestata alfa ni, saj se konestat alfa očisti iz krvnega obtoka s presnovo v jetrih z od receptorja odvisno endocitozo, ki ji sledi popolna hidroliza/razgradnja.
There is no experience from clinical trials with Voncento in previously untreated patients (PUPs).
Izkušenj iz kliničnih preskušanj z zdravilom Voncento pri predhodno nezdravljenih bolnikih (PNB) ni.
There is no experience from controlled clinical trials with concomitant use of Samsca and other treatments for hyponatraemia such as hypertonic saline, oral sodium formulations, and medicinal products that increase serum sodium concentration.
Izkušenj iz kontroliranih kliničnih preskušanj sočasne uporabe zdravila Samsca in drugih oblik zdravljenja hiponatriemije, kot so hipertonična fiziološka raztopina, peroralne oblike natrija in zdravila, ki povečajo koncentracije natrija v serumu, ni.
There is no experience from controlled clinical trials with concomitant use of tolvaptan and hypertonic saline, oral sodium formulations, and medicinal products that increase serum sodium concentration.
Ni izkušenj iz nadzorovanih kliničnih preskušanj s sočasno uporabo tolvaptana in hipertonične raztopine, peroralnimi natrijevimi pripravki in zdravili, ki zvišujejo koncentracije natrija v serumu.
There is no experience in children and adolescents (see section 4.4).
Izkušenj pri otrocih in mladostnikih ni (glejte poglavje 4.4).
There is no experience in children under 2 years.
Pri otrocih, mlajših od 2 let, ni izkušenj
There is no experience in elderly patients.
Izkušenj pri starostnikih ni.
There is no experience in patients >65 years.
Izkušenj pri bolnikih, starejših od 65 let, ni.
There is no experience in patients with congestive heart failure NYHA class III-IV and Xultophy is therefore not recommended in these patients.
Izkušenj pri zdravljenju bolnikov s srčnim popuščanjem razreda III–IV po razvrstitvi NYHA ni, zato uporaba zdravila Xultophy pri teh bolnikih ni priporočljiva.
There is no experience in patients with congestive heart failure NYHA class III­IV and liraglutide is therefore not recommended in these patients.
Izkušenj pri zdravljenju bolnikov s srčnim popuščanjem razreda III–IV po razvrstitvi NYHA ni in zato uporaba liraglutida pri teh bolnikih ni priporočena.
There is no experience in surgery of paediatric patients.
Pri pediatričnih bolnikih ni izkušenj pri kirurških posegih.
There is no experience in the treatment of
Ni izkušenj z zdravljenjem
There is no experience in the use of mitotane in patients with hepatic impairment, so data are insufficient to give a dose recommendation in this group.
Pri uporabi mitotana pri bolnikih z jetrno okvaro ni izkušenj, zato ni dovolj podatkov, s katerimi bi se lahko priporočil odmerek za to skupino bolnikov.
There is no experience in the use of mitotane in patients with renal impairment, so data are insufficient to give a dose recommendation in this group.
Pri uporabi mitotana pri bolnikih z ledvično okvaro ni izkušenj, zato ni podatkov s katerimi bi se lahko priporočil odmerek za to skupino bolnikov.
There is no experience of concomitant administration of Lucentis and Visudyne.
S sočasno uporabo zdravil Lucentis in Visudyne ni nobenih izkušenj.
There is no experience of DuoTrav in inflammatory ocular conditions; nor in neovascular, angle-closure, narrow-angle or congenital glaucoma and only limited experience in thyroid eye disease, in open-angle glaucoma of pseudophakic patients and in pigmentary or pseudoexfoliative glaucoma.
Ni izkušenj z uporabo zdravila DuoTrav pri vnetnih očesnih boleznih niti pri neovaskularnem glavkomu, glavkomu z zaprtim zakotjem, glavkomu z ozkim zakotjem, ali pri kongenitalnem glavkomu, izkušnje pri prizadetosti oči pri boleznih ščitnice, glavkomu z odprtim zakotjem pri psevdofakičnih bolnikih ter pri pigmentnem ali psevdoeksfoliativnem glavkomu pa so omejene.
There is no experience of initiating treatment with lumacaftor/ivacaftor in patients having a pulmonary exacerbation and this is not advisable.
Nimamo izkušenj z uvajanjem zdravljenja z lumakaftorjem/ivakaftorjem pri bolnikih s pljučnim poslabšanjem in to ni priporočljivo.
There is no experience of overdose with Trizivir.
Izkušenj s prevelikim odmerjanjem zdravila Trizivir ni.
There is no experience of the treatment of previously untreated patients with Nonafact.
Izkušenj pri zdravljenju predhodno še nezdravljenih bolnikov z zdravilom Nonafact ni.
There is no experience of the treatment of previously untreated patients with Nonafact.
Izkušenj z zdravljenjem z zdravilom Nonafact pri bolnikih, ki predhodno še niso bili zdravljeni, ni.
There is no experience of the use of delamanid in patients receiving concomitant therapy against HIV (see section 4.5).
Z uporabo delamanida pri bolnikih, ki sočasno prejemajo terapijo proti HIV, ni izkušenj (glejte poglavje 4.5).
There is no experience of the use of Kalydeco in patients with severe hepatic impairment and therefore its use is not recommended unless the benefits outweigh the risks.
Izkušenj z uporabo zdravila Kalydeco pri bolnikih s težkimi okvarami jeter ni in zato uporabe zdravila Kalydeco pri teh bolnikih ne priporočajo, razen če koristi zdravljenja odtehtajo tveganje.
There is no experience of the use of Kalydeco in patients with severe hepatic impairment and therefore its use is not recommended unless the benefits outweigh the risks.
Uporabe ivakaftorja pri bolnikih s težko okvaro jeter zato ni priporočljiva, razen če pričakovana korist odtehta tveganja.
There is no experience of the use of NexoBrid on:
Z uporabo zdravila NexoBrid ni izkušenj pri:
There is no experience of the use of Orkambi in patients with severe hepatic impairment (Child-Pugh Class C), but exposure is expected to be higher than in patients with moderate hepatic impairment.
Izkušenj z uporabo zdravila Orkambi pri bolnikih s težkimi okvarami jeter (razred C po Child-Pughovi lestvici) ni, a se pričakuje, da bo izpostavljenost večja kot pri bolnikih z zmerno okvaro jeter.
There is no experience of treating actinic keratosis lesions in patients with dark brown or black skin (skin sun sensitivity type V or VI according to Fitzpatrick).
Ni izkušenj z zdravljenjem lezij aktinične keratoze pri bolnikih s temno rjavo ali črno kožo (občutljivost kože na sonce tipa V ali VI po Fitzpatricku).
There is no experience of treating severe actinic keratoses or lesions which are pigmented or highly infiltrating.
Ni izkušenj z zdravljenjem hude aktinične keratoze ali lezij, ki so pigmentirane ali močno infiltrirajoče.
There is no experience of using Eylea in pregnant women.
Izkušenj z uporabo zdravila Eylea pri nosečnicah ni.
There is no experience of using Lucentis in pregnant women; therefore the potential risks are unknown.
Z uporabo zdravila Lucentis v nosečnosti ni nobenih izkušenj, zato morebitna tveganja niso znana.
There is no experience of using Macugen in pregnant women.
Ni podatkov o uporabi zdravila Macugen pri nosečih ženskah.
There is no experience regarding the administration of Kinzalmono in patients with recent kidney transplantation.
Pri bolnikih z nedavno presajeno ledvico ni izkušenj z uporabo Kinzalmonoa.
There is no experience regarding the administration of Rasilez HCT in patients who have recently undergone kidney transplantation.
Izkušenj z uporabo zdravila Rasilez HCT pri bolnikih, ki so jim pred kratkim presadili ledvico, ni.
There is no experience regarding the administration of Sabervel in patients with a recent kidney transplantation.
Glede uporabe zdravila Sabervel pri bolnikih po nedavni presaditvi ledvic ni nobenih izkušenj.
There is no experience regarding the administration of Telmisartan Actavis in patients with recent kidney transplantation.
Izkušenj z uporabo zdravila Telmisartan Actavis pri bolnikih, ki jim je bila pred kratkim presajena ledvica, ni.
There is no experience regarding the withdrawal of concomitant use of anti-epileptic medicinal products during treatment with Zebinix (i.e. switching to monotherapy).
Izkušenj z odtegnitvijo antiepileptikov, ki se uporabljajo sočasno z zdravilom Zebinix (t.j. prehod na samostojno zdravljenje), ni.
There is no experience with administration of intravenous levetiracetam for a longer period than 4 days.
Ni izkušenj z intravensko uporabo levetiracetama za obdobje daljše od 4 dni.
There is no experience with administration of intravenous levetiracetam for a longer period than 4 days.
Ni izkušenj z intravensko uporabo levetiracetama za obdobje, daljše od 4 dni.
There is no experience with administration of intravenous levetiracetam for longer period than 4 days.
Za obdobje daljše od 4 dni ni izkušenj z intravensko uporabo levetiracetama.
There is no experience with administration of intravenous levetiracetam for longer period than 4 days.
Za obdobje, daljše od 4 dni, ni izkušenj z intravensko uporabo levetiracetama.
There is no experience with asenapine in patients with severe renal impairment who have a creatinine clearance less than 15 mL/min.
Z uporabo asenapina pri bolnikih s hudo okvaro ledvic, ki imajo očistek kreatinina manjši od 15 ml/min, izkušenj ni.
There is no experience with asenapine in severe renal impairment patients with a creatinine clearance less than 15 mL/min.
Ni izkušenj z uporabo asenapina pri bolnikih s hudo okvaro ledvic, ki imajo očistek kreatinina manjši od 15 ml/min.
There is no experience with ceftaroline in the treatment of CAP in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, severe underlying lung disease, those with PORT Risk Class V, and/or CAP requiring ventilation at presentation, CAP due to methicillin- resistant S. aureus or patients requiring intensive care.
O zdravljenju zunajbolnišnične pljučnice s ceftarolinom ni nobenih izkušenj pri naslednjih skupinah bolnikov: pri imunsko oslabelih bolnikih, bolnikih s hudo sepso/septičnim šokom, hudo osnovno boleznijo pljuč, bolnikih, ki se uvrščajo v V. razred tveganja po sistemu PORT, in/ali bolnikih z zunajbolnišnično pljučnico, ki so ob sprejemu potrebovali ventilacijo, pri bolnikih z zunajbolnišnično pljučnico, katere povzročitelj je proti meticilinu odporni S. aureus, ter pri bolnikih, ki potrebujejo intenzivno nego.
There is no experience with dalbavancin in the treatment of severely immunocompromised patients.
Izkušenj z dalbavancinom pri zdravljenju pacientov s hudo oslabljenim imunskim sistemom ni.
There is no experience with dose reduction/increase or modification of the schedule in the treatment of extravasation.
Izkušenj o zniževanju/zviševanju odmerka ali spremembah urnika zdravljenja ekstravazacij ni.
There is no experience with EXUBERA in patients with infection of the deep lung (pneumonia).
Z uporabo zdravila EXUBERA ni izkušenj pri bolnikih, ki imajo okužbo globoko v pljučih (pljučnico).
There is no experience with Kepivance doses greater than 80 micrograms/kg/day administered intravenously in patients over 2 weeks (3 doses preceding and 3 doses following myeloablative therapy).
Z zdravilom Kepivance ni izkušenj v odmerkih, večjih od 80 mikrogramov/kg/dan, apliciranih intravensko v obdobju 2 tednov (3 odmerki pred in 3 odmerki po mieloablacijski terapiji).
There is no experience with lepirudin in patients with significant liver impairment.
Ni poročil o izkušnjah z lepirudinom pri bolnikih s pomembno okvaro jeter.
There is no experience with Myocet in patients with a history of cardiovascular disease, e.g. myocardial infarction within 6 months prior to treatment.
Ni izkušenj z uporabo zdravila Myocet pri bolnicah, ki so imele v zadnjih 6 mesecih pred zdravljenjem kardiovaskularno bolezen, npr. miokardni infarkt.
There is no experience with opicapone when used concomitantly with OATP1B1 substrates.
Izkušenj z opikaponom, uporabljemen sočasno s substrati OATP1B1, ni.
There is no experience with overdose of Myozyme.
S prevelikim odmerjanjem zdravila Myozyme ni izkušenj.
There is no experience with overdose of Neupopeg in humans.
S prevelikim odmerjanjem Neupopega pri ljudeh ni izkušenj.
There is no experience with Revasc in children.
Pri otrocih ni izkušenj z Revascom.
There is no experience with the reinstitution of EXUBERA therapy in patients whose lung function recovers.
Pri bolnikih, ki se jim delovanje pljuč popravi, ni izkušenj s ponovno uvedbo EXUBERE.
There is no experience with the treatment of children below 2 years of age.
Z zdravljenjem otrok in mladostnikov, mlajših od 2 let, ni nobenih izkušenj.
There is no experience with the use of Kentera in patients with renal impairment.
Izkušenj z uporabo zdravila Kentera pri bolnikih z ledvično okvaro ni.
There is no experience with the use of Toujeo in children below the age of 2 years.
Pri otrocih, mlajših od 2 let, izkušenj z uporabo zdravila Toujeo ni.
There is no experience with twice daily intravenous administration of brivaracetam for a period longer than 4 days.
Z intravensko uporabo brivaracetama dvakrat na dan v obdobju, daljšem od 4 dni, ni izkušenj.
There is no gender difference in the pharmacokinetic properties of Ryzodeg.
Farmakokinetične značilnosti zdravila Ryzodeg se med spoloma ne razlikujejo.
There is no gender difference in the pharmacokinetic properties of Tresiba.
Farmakokinetične značilnosti zdravila Tresiba se med spoloma ne razlikujejo.
There is no gender effect on pharmacokinetic parameters.
Spol živali nima vpliva na farmakokinetične parametre.
There is no human experience of overdose.
Pri ljudeh ni izkušenj s prevelikim odmerjanjem.
There is no human experience with elotuzumab during pregnancy.
Izkušenj z uporabo elotuzumaba med nosečnostjo pri človeku ni.
There is no indication for use of Bemfola during pregnancy.
Za uporabo zdravila Bemfola med nosečnostjo ni indikacij.
There is no indication that the efficacy or safety of FIRMAGON treatment is affected by antibody formation after up to 5.5 years of treatment.
Nič ne kaže, da bi nastajanje protiteles vplivalo na učinkovitost ali varnost zdravljenja z zdravilom FIRMAGON po zdravljenju do, ki traja 5,5 let.
There is no information about the safety of Arzerra in pregnant women.
O varnosti zdravila Arzerra pri nosečnicah ni podatkov.
There is no information about the use of Ceplene in pregnant women.
O uporabi zdravila Ceplene v času nosečnosti ni nobenih podatkov.
There is no information available about interactions of Ceplene with food, drink and alcohol.
Podatkov o medsebojnem delovanju zdravila Ceplene s hrano, pijačo in alkoholom ni na voljo.
There is no information available about the pharmacokinetics of pegbovigrastim in cattle.
Ni podatkov o farmakokinetiki pegbovigrastima pri govedu.
There is no information available concerning the first and the third trimesters.
O uporabi zdravila v prvem ali tretjem trimesečju ni podatkov.
There is no information available on clinical use of Episalvan for more than 4 weeks.
Podatkov o klinični uporabi zdravila Episalvan, ki presega 4 tedne ni na voljo.
There is no information available on its effectiveness in patients whose disease is in ‘blast crisis’ (another phase of CML).
Podatki o učinkovitosti tega zdravila pri bolnikih, pri katerih je bolezen v blastni krizi (še ena faza kronične mieloične levkemije) niso na voljo.
There is no information available on maternal-foetal transmission of hepatitis B virus in pregnant women receiving treatment with lamivudine.
Pri nosečnicah, ki se zdravijo z lamivudinom, ni podatkov o prenosu virusa hepatitisa B z matere na plod.
There is no information available on the use of ACOMPLIA in people under 18 years of age.
Podatkov o uporabi zdravila ACOMPLIA pri osebah, mlajših od 18 let, ni.
There is no information for the use of CellCept in children with a heart transplant.
Podatki o uporabi zdravila CellCept pri otrocih s srčnim presadkom niso na voljo.
There is no information for the use of CellCept in children with a liver transplant.
Podatki o uporabi zdravila CellCept pri otrocih z jetrnim presadkom niso na voljo.
There is no information for the use of Myclausen in children with a heart transplant.
Podatki o uporabi zdravila Myclausen pri otrocih s srčnim presadkom niso na voljo.
There is no information for the use of Myclausen in children with a liver transplant.
Podatki o uporabi zdravila Myclausen pri otrocih z jetrnim presadkom niso na voljo.
There is no information from the use of Xadago in pregnant women, but animal studies indicate harmful effects on the foetus following administration during pregnancy.
Podatkov o uporabi zdravila Xadago pri nosečnicah ni, vendar študije na živalih kažejo škodljive učinke na plod med nosečnostjo po dajanju zdravila.
There is no information on administration of VEPACEL with other vaccines.
Ni podatkov o sočasnem cepljenju s cepivom VEPACEL in drugimi cepivi.
There is no information on its effects in patients who have not been treated before or who have been treated with many different anti-HIV medicines in the past.
Podatkov o učinkih pri bolnikih, ki se še niso zdravili ali ki so se zdravili z več različnimi zdravili proti okužbi z virusom HIV, ni.
There is no information on its use in children and adolescents.
Na voljo ni podatkov o uporabi zdravila pri otrocih in mladostnikih.
There is no information on switching to Celsentri from another type of medicine for HIV infection in patients whose HIV is being treated successfully, when no virus can be detected in their blood.
Ni podatkov o odzivu na prehod na zdravilo Celsentri z drugega zdravila za zdravljenje okužbe z virusom HIV pri bolnikih, pri katerih je okužba zdravljena uspešno in kadar v krvi virusa ni zaznati.
There is no information on the effect of Mycamine on the ability to drive or use machines.
Ni podatkov, da bi zdravilo Mycamine vplivalo na sposobnost upravljanja vozil ali strojev.
There is no information on the effect on the transdermal patch of activities such as strenuous exercise or the use of sauna or whirlpools; therefore, you should avoid these activities while wearing SANCUSO.
Ni podatkov o vplivu (fizičnih) aktivnosti, kot so na primer naporna vadba ali uporabe savne ali masažnih bazenov, na transdermalni obliž; zato se takrat, ko nosite obliž SANCUSO, izogibajte tem dejavnostim.
There is no information on the effects of rFIX on fertility.
O učinku rekombinantnega koagulacijskega faktorja IX na plodnost ni podatkov.
There is no information on the excretion of nintedanib and its metabolites in human milk.
Ni dovolj podatkov o izločanju nintedaniba in njegovih presnovkov v materino mleko.
There is no information on the use of Betaferon in children under 12 years of age.
Ni informacij o uporabi zdravila Betaferon pri otrocih, starih manj kot 12 let.
There is no information on the use of docetaxel in pregnant women.
O zdravljenju z docetakselom pri bolnikih s hudo okvaro ledvic ni podatkov.
There is no information on the use of Vargatef in pregnant women, but pre-clinical studies in animals have shown reproductive toxicity of this active substance (see section 5.3).
Ni podatkov o uporabi zdravila Vargatef pri nosečnicah, vendar predklinične študije pri živalih kažejo na reproduktivno toksičnost te zdravilne učinkovine (glejte poglavje 5.3).
There is no information on the use of VEPACEL under the skin.
O podkožni uporabi cepiva VEPACEL ni podatkov.
There is no information to suggest that Cancidas affects your ability to drive or operate machinery.
Ni podatkov, ki bi kazali, da zdravilo Cancidas vpliva na sposobnost vožnje ali upravljanja s stroji.
There is no information to suggest that M-M-RVAXPRO affects the ability to drive or operate machinery.
Ni podatkov, ki bi kazali, da cepivo M-M-RVAXPRO vpliva na sposobnost vožnje ali upravljanja s stroji.
There is no known antidote for overdose of ONIVYDE.
Za preveliko odmerjanje zdravila ONIVYDE ni znanega antidota.
There is no known antidote for trastuzumab emtansine overdose.
Za preveliko odmerjanje trastuzumaba emtanzina ni znanega antidota.
There is no known antidote to fondaparinux.
Antidot za fondaparinuks ni znan.
There is no known antidote to Ketoconazole HRA.
Za zdravilo Ketokonazol HRA ni znanega antidota.
There is no known benefit from injecting the extravasation site with another substance.
Koristi pri injiciranju drugega zdravila na mesto ekstravazacije niso znane.
There is no known cross-resistance between telavancin and other non-glycopeptide classes of antibiotics.
Ni znane navzkrižne odpornosti med telavancinom in drugimi neglikopeptidnimi razredi antibiotikov.
There is no known interaction between Hycamtin and alcohol.
Med zdravilom Hycamtin in alkoholom ni znanega medsebojnega delovanja.
There is no known interaction between Hycamtin and alcohol.
Medsebojno delovanje med zdravilom Hycamtin in alkoholom ni znano.
There is no known specific antidote for [90Y]-radiolabelled Zevalin overdosage.
Specifično protisredstvo za preveliko odmerjanje z [90Y] označenega zdravila Zevalin ni znano.
There is no LEMTRADA treatment between the two courses.
Med obema postopkoma se ne boste zdravili zdravilom LEMTRADA.
There is no meaningful difference in the PK of apremilast between mild or moderate renal impaired subjects and matched healthy subjects (N=8 each).
Ni pomembnih razlik v PK apremilasta med preiskovanci z blago ali zmerno okvaro ledvic in primerljivimi zdravimi preiskovanci (N=8 vsakih).
There is no need for contraceptive measures in women of childbearing potential treated with cholic acid or their partners.
Pri ženskah v rodni dobi, ki se zdravijo s holno kislino, ali njihovih partnerjih ni potrebna kontracepcija.
There is no need for dosage adjustment in patients with mild to moderate renal impairment.
Pri bolnikih z blago do zmerno okvarjenim delovanjem ledvic ni treba prilagajati odmerka.
There is no need for dose adjustment in mild to moderate hepatic impairment.
Pri bolnikih z blago do zmerno okvarjenim delovanjem jeter ni treba prilagajati odmerka.